Spermosens (SPERM) Q2 2024 earnings summary

Executive summary

• Revised strategy centers on clinical validation and commercialization of JUNO-Checked, targeting male infertility diagnostics and global partnerships.

• Tore Duvold appointed as new CEO; focus on cost reduction and operational efficiency.

• Patent approval secured in Singapore, expanding IP protection.

• Entered agreement with ScanMed Partners to accelerate US market entry.

Financial highlights

• Net sales remained at SEK 0 for Q2 and H1 2024, unchanged from prior year.

• Operating loss for Q2 was SEK -2,055k (improved from -3,400k Q2 2023); H1 operating loss SEK -4,659k (improved from -6,648k H1 2023).

• Net loss for Q2 was SEK -2,367k (vs. -3,429k Q2 2023); H1 net loss SEK -5,583k (vs. -6,704k H1 2023).

• Cash and cash equivalents at period end SEK 2,959k (vs. 6,758k prior year).

• Rights issue in April raised SEK 24.2m before SEK 7.0m in issue costs.

Outlook and guidance

• Clinical study for JUNO-Checked to begin in Q3 2024 at RMC Malmö, aiming to demonstrate diagnostic efficacy.

• Business development efforts to expand in North America and other key geographies.

• Current cash position insufficient for next 12 months; additional capital raising prioritized.